154 related articles for article (PubMed ID: 28133444)
41. Rhes Counteracts Dopamine Neuron Degeneration and Neuroinflammation Depending on Gender and Age.
Costa G; Pinna A; Porceddu PF; Casu MA; Di Maio A; Napolitano F; Usiello A; Morelli M
Front Aging Neurosci; 2018; 10():163. PubMed ID: 29904346
[TBL] [Abstract][Full Text] [Related]
42. A WNT1-regulated developmental gene cascade prevents dopaminergic neurodegeneration in adult En1(+/-) mice.
Zhang J; Götz S; Vogt Weisenhorn DM; Simeone A; Wurst W; Prakash N
Neurobiol Dis; 2015 Oct; 82():32-45. PubMed ID: 26049140
[TBL] [Abstract][Full Text] [Related]
43. Epigenetic mechanisms in the development and maintenance of dopaminergic neurons.
van Heesbeen HJ; Mesman S; Veenvliet JV; Smidt MP
Development; 2013 Mar; 140(6):1159-69. PubMed ID: 23444349
[TBL] [Abstract][Full Text] [Related]
44. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease.
Liang CL; Wang TT; Luby-Phelps K; German DC
Exp Neurol; 2007 Feb; 203(2):370-80. PubMed ID: 17010972
[TBL] [Abstract][Full Text] [Related]
45. Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3.
Smidt MP; Smits SM; Bouwmeester H; Hamers FP; van der Linden AJ; Hellemons AJ; Graw J; Burbach JP
Development; 2004 Mar; 131(5):1145-55. PubMed ID: 14973278
[TBL] [Abstract][Full Text] [Related]
46. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
[TBL] [Abstract][Full Text] [Related]
47. [Expression of imprinted Igf2 and Peg1/Mest genes in postimplantation parthenogenetic mouse embryos treated with transforming growth factor alpha in vitro].
Penkov LI; Kondrakhina MS; Mironova OV; Platonov ES
Genetika; 2008 Aug; 44(8):1148-52. PubMed ID: 18825967
[TBL] [Abstract][Full Text] [Related]
48. Activity-dependent regulation of the dopamine phenotype in substantia nigra neurons.
Aumann T; Horne M
J Neurochem; 2012 May; 121(4):497-515. PubMed ID: 22356203
[TBL] [Abstract][Full Text] [Related]
49. Characteristics of electrically evoked somatodendritic dopamine release in substantia nigra and ventral tegmental area in vitro.
Rice ME; Cragg SJ; Greenfield SA
J Neurophysiol; 1997 Feb; 77(2):853-62. PubMed ID: 9065854
[TBL] [Abstract][Full Text] [Related]
50. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
[TBL] [Abstract][Full Text] [Related]
51. Pitx3 potentiates Nurr1 in dopamine neuron terminal differentiation through release of SMRT-mediated repression.
Jacobs FM; van Erp S; van der Linden AJ; von Oerthel L; Burbach JP; Smidt MP
Development; 2009 Feb; 136(4):531-40. PubMed ID: 19144721
[TBL] [Abstract][Full Text] [Related]
52. Pitx3 deficiency produces decreased dopamine signaling and induces motor deficits in Pitx3(-/-) mice.
Le W; Zhang L; Xie W; Li S; Dani JA
Neurobiol Aging; 2015 Dec; 36(12):3314-3320. PubMed ID: 26363812
[TBL] [Abstract][Full Text] [Related]
53. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats.
Pang Y; Lin S; Wright C; Shen J; Carter K; Bhatt A; Fan LW
Neuroscience; 2016 Mar; 318():157-65. PubMed ID: 26777890
[TBL] [Abstract][Full Text] [Related]
54. LPA signaling is required for dopaminergic neuron development and is reduced through low expression of the LPA1 receptor in a 6-OHDA lesion model of Parkinson's disease.
Yang XY; Zhao EY; Zhuang WX; Sun FX; Han HL; Han HR; Lin ZJ; Pan ZF; Qu MH; Zeng XW; Ding Y
Neurol Sci; 2015 Nov; 36(11):2027-33. PubMed ID: 26169757
[TBL] [Abstract][Full Text] [Related]
55. Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout.
Giguère N; Delignat-Lavaud B; Herborg F; Voisin A; Li Y; Jacquemet V; Anand-Srivastava M; Gether U; Giros B; Trudeau LÉ
PLoS Genet; 2019 Aug; 15(8):e1008352. PubMed ID: 31449520
[TBL] [Abstract][Full Text] [Related]
56. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.
Marinova-Mutafchieva L; Sadeghian M; Broom L; Davis JB; Medhurst AD; Dexter DT
J Neurochem; 2009 Aug; 110(3):966-75. PubMed ID: 19549006
[TBL] [Abstract][Full Text] [Related]
57. Effects of chronic, systemic treatment with the dopamine receptor agonist R-apomorphine in partially lesioned rat model of Parkinson's disease: an electrophysiological study of substantia nigra dopamine neurons.
Gui ZH; Liu J; Wang Y; Ali U; Wang T; Chen L
Chin J Physiol; 2011 Apr; 54(2):96-104. PubMed ID: 21789890
[TBL] [Abstract][Full Text] [Related]
58. Differential contribution of Ih to the integration of excitatory synaptic inputs in substantia nigra pars compacta and ventral tegmental area dopaminergic neurons.
Masi A; Narducci R; Resta F; Carbone C; Kobayashi K; Mannaioni G
Eur J Neurosci; 2015 Nov; 42(9):2699-706. PubMed ID: 26354486
[TBL] [Abstract][Full Text] [Related]
59. Role for VGLUT2 in selective vulnerability of midbrain dopamine neurons.
Steinkellner T; Zell V; Farino ZJ; Sonders MS; Villeneuve M; Freyberg RJ; Przedborski S; Lu W; Freyberg Z; Hnasko TS
J Clin Invest; 2018 Feb; 128(2):774-788. PubMed ID: 29337309
[TBL] [Abstract][Full Text] [Related]
60. Otx2 expression is restricted to dopaminergic neurons of the ventral tegmental area in the adult brain.
Di Salvio M; Di Giovannantonio LG; Omodei D; Acampora D; Simeone A
Int J Dev Biol; 2010; 54(5):939-45. PubMed ID: 19924631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
